Ferring v. Jiangsu Hansoh: FIRMAGON® Degarelix Patent Dispute Settled in 118 Days
Ferring Pharmaceuticals and its affiliates filed a four-patent infringement action against Chinese generic pharmaceutical group Jiangsu Hansoh over FIRMAGON® (degarelix acetate) for injection — a GnRH receptor antagonist used in prostate cancer treatment. The parties agreed to settlement terms within 118 days of filing, with the case voluntarily dismissed before trial.
Ferring’s FIRMAGON® Patent Portfolio Triggers Early Settlement with Hansoh
On July 19, 2024, Ferring Pharmaceuticals, Inc., Ferring International Center S.A., and Ferring B.V. (collectively ‘Ferring’) filed an infringement action in the U.S. District Court for the District of New Jersey against Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a major Chinese pharmaceutical manufacturer. The dispute centred on FIRMAGON® (degarelix acetate) for injection in 80 mg and 120 mg dosages, a branded GnRH receptor antagonist indicated for advanced prostate cancer. Ferring asserted four U.S. patents: US8841081B2, US11826397B2, US11766468B2, and US9877999B2.
The case closed on November 14, 2024 — just 118 days after filing — following a voluntary dismissal entered after the parties reached a settlement agreement. The public record confirms that Ferring and Hansoh ‘agreed to terms and conditions for a settlement agreement,’ though the specific commercial terms, any licence grant, launch date restrictions, or royalty arrangements remain confidential. No merits adjudication was reached, meaning no court determined validity or infringement of any asserted patent.
A resolution within four months of filing is notably swift for a branded pharmaceutical patent case of this scope, particularly one involving a four-patent portfolio and a Chinese generic challenger. The speed suggests the parties may have entered pre-litigation discussions or that the settlement framework was substantially negotiated before or shortly after the complaint was filed. What drove the specific terms — whether market entry timing, royalty rates, or territorial restrictions — is not disclosed in the public docket, leaving the competitive implications of the settlement opaque.
Filing to Voluntary dismissal in 118 days
118 days — resolved before most pharma patent cases reach claim construction
Voluntarily dismissed: what this settlement exit means for both parties
Voluntary dismissal following confirmed settlement agreement
A voluntary dismissal under Federal Rules of Civil Procedure terminates the case without a court ruling on the merits. Here, the dismissal was expressly tied to a settlement agreement between Ferring and Hansoh. The public record does not specify whether the dismissal was with or without prejudice — a legally significant distinction that determines whether Ferring could re-file on the same claims. Neither party has disclosed the prejudice classification.
No merits rulingWith or without prejudice? The public record is silent
A dismissal ‘with prejudice’ bars the plaintiff from re-filing the same claims — permanently resolving the dispute. A dismissal ‘without prejudice’ preserves the right to re-file. In ANDA-linked pharmaceutical patent litigation, the prejudice classification can significantly affect whether a generic manufacturer obtains certainty of market entry. The docket here records only ‘Voluntary dismissal’ without specifying either classification, leaving the enforceability posture of Ferring’s four patents against Hansoh publicly ambiguous.
Prejudice status undisclosedFerring’s four-patent FIRMAGON® portfolio remains unchallenged on the merits
Because the case ended via settlement before any claim construction, invalidity determination, or infringement ruling, all four asserted patents — US8841081B2, US11826397B2, US11766468B2, and US9877999B2 — retain their presumption of validity. Ferring can continue asserting this portfolio against other potential generic entrants. The settlement terms may include agreed launch dates or licences that structure Hansoh’s U.S. market access without public disclosure.
Portfolio validity preservedEarly resolution limits precedent but signals defensive patent strength
Hansoh’s decision to settle within 118 days — before substantive motion practice — is consistent with a calculation that litigation risk outweighed negotiated entry terms. For other generic manufacturers eyeing degarelix acetate in the U.S. market, this outcome provides no invalidity or non-infringement precedent against Ferring’s portfolio. Any prospective entrant would need to independently assess all four asserted patents before filing an ANDA with Paragraph IV certifications.
No invalidity precedent setFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ferring Pharmaceuticals, Inc. | Company | Branded pharmaceutical group — holder of US8841081B2 and three further degarelix patentsSearch in Eureka ↗ |
| Co-Plaintiff | Ferring International Center S.A. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Ferring B.V. | Individual | Search in Eureka ↗ |
| Defendant | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. | Company | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. — major Chinese generic and specialty pharma manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text confirms a settlement agreement was reached between Ferring and Hansoh but provides no detail on commercial terms, prejudice status, or patent scope. The phrasing — ‘agreed to terms and conditions for a settlement agreement’ — is formulaic and intentionally non-specific, which is consistent with confidential pharmaceutical settlement practice. No court assessed the validity or infringement of any of the four asserted patents, meaning the legal strength of Ferring’s FIRMAGON® portfolio is neither confirmed nor impaired by this disposition.
US8841081B2 — Degarelix acetate formulation for GnRH receptor antagonism
US8841081B2 (application no. US12/368713) is the anchor patent in Ferring’s asserted portfolio, covering degarelix acetate pharmaceutical compositions used in FIRMAGON® — an injectable GnRH receptor antagonist approved for advanced prostate cancer. The three additional patents (US11826397B2, US11766468B2, US9877999B2) span formulation methods, manufacturing processes, and therapeutic dosing, collectively creating overlapping exclusivity across the product lifecycle. The portfolio’s application dates span multiple continuation and divisional filings, suggesting deliberate prosecution strategy to extend protection depth.
FIRMAGON® occupies a specialist oncology niche as one of few approved GnRH receptor antagonists for prostate cancer, differentiating it from GnRH agonists on the basis of faster testosterone suppression. Ferring’s four-patent portfolio around the 80 mg and 120 mg injectable presentations creates a formidable IP barrier for generic entrants seeking ANDA approval with Paragraph IV certifications. Any competitor targeting this product must address composition, formulation, and method claims simultaneously — a resource-intensive challenge that likely influenced Hansoh’s decision to settle rather than litigate.
Should your team run an FTO against Ferring’s degarelix patent portfolio?
Any pharmaceutical company developing or commercialising a degarelix acetate injectable product for the U.S. market — whether as an ANDA filer, 505(b)(2) applicant, or biosimilar-adjacent developer — should conduct a freedom-to-operate analysis against all four asserted patents. US8841081B2, US11826397B2, US11766468B2, and US9877999B2 collectively cover formulation composition, manufacturing methods, and therapeutic use, meaning a product that avoids one claim family may still infringe another. The absence of any invalidity ruling from this case means all four patents carry full presumption of validity.
PatSnap Eureka’s FTO Search Agent can map your degarelix formulation parameters against the claim scope of all four Ferring patents simultaneously, flagging overlap risks across composition, process, and method-of-use claims. Eureka’s citation and prosecution history analysis can also identify potential design-around opportunities and reveal whether continuation applications are pending that could extend the exclusivity timeline. For R&D and regulatory teams planning U.S. market entry for GnRH receptor antagonist injectables, this analysis is a prerequisite before ANDA filing.
Run a freedom-to-operate analysis on US8841081B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent disputes over GnRH antagonist and oncology injectable IP
Explore comparable pharmaceutical patent infringement cases in the District of New Jersey involving ANDA challenges to branded oncology injectable formulations and GnRH antagonist products.
What this case signals for the GnRH antagonist and pharma IP landscape
A four-patent settlement in 118 days reveals how branded pharma groups defend blockbuster injectable oncology products against generic entry.
Four-patent stacking is a standard defensive tactic for branded injectables
Ferring asserted four separate U.S. patents covering degarelix formulations and methods. This layered portfolio approach — spanning composition, formulation, and method-of-use claims — forces any generic challenger to clear multiple validity hurdles simultaneously. Early settlement here suggests Hansoh assessed the cost and risk of that multi-front challenge and concluded negotiated terms were preferable.
No merits ruling means the FIRMAGON® patent wall stays intact for future challengers
Because no court ruled on validity or infringement, Ferring’s four-patent portfolio is undiminished as a litigation asset. Any subsequent ANDA filer for degarelix acetate would face the same portfolio without the benefit of precedential claim constructions or invalidity findings from this proceeding. Companies monitoring generic entry windows for FIRMAGON® should treat all four patents as live enforcement risks.
Ferring v JIANGSU — key questions answered
Ferring asserted four U.S. patents: US8841081B2, US11826397B2, US11766468B2, and US9877999B2. All four relate to FIRMAGON® (degarelix acetate) for injection in 80 mg and 120 mg presentations, covering formulation compositions, manufacturing methods, and therapeutic use for advanced prostate cancer.
The case was voluntarily dismissed on November 14, 2024, following a settlement agreement between Ferring and Hansoh. The specific commercial terms — including any licence, authorised generic rights, or agreed market entry date — were not disclosed in the public record. No court ruled on the validity or infringement of any of the four asserted patents.
FIRMAGON® is a branded GnRH receptor antagonist injectable indicated for advanced prostate cancer, marketed by Ferring. It suppresses testosterone more rapidly than GnRH agonists. The litigation suggests Jiangsu Hansoh sought U.S. regulatory approval — likely via an ANDA — for a generic degarelix acetate product, triggering Ferring’s multi-patent infringement action to protect market exclusivity.
No. Because the case ended via voluntary dismissal before any merits adjudication, no court construed the claims or assessed the validity of any of Ferring’s four asserted patents. Any subsequent ANDA filer for degarelix acetate must independently challenge the same portfolio without the benefit of prior invalidity or claim construction rulings from this case.
The precise reasons are not disclosed in the public record. However, resolution within 118 days in a four-patent pharmaceutical dispute is consistent with pre-litigation negotiation or early agreement on commercial terms. It suggests Hansoh calculated that negotiating a licenced or delayed market entry was preferable to the cost and uncertainty of litigating four patents to judgment. The settlement terms, which may include launch date restrictions or royalties, remain confidential.
PatSnap Eureka searches patents and litigation data to answer instantly.